Entry comments: I bought this speculative afterhours news http://tim.ly/2DwXUj1 should be a PR on Monday, goal is to make 15-30% as these biotechs have been spiking big and I think most people have left for the week so this might be an opportunity...already hit the 1.40s so I'm buying on slight dip
Exit comments: Got up to 1.55 but now there's a solid wall of sellers so it doesn't seem like this will be the big afterhours runner I thought it might be...taking small profits, potential re-buy on any big dip
| Date | Price | |
|---|---|---|
| Entry | 3/16/2018 | 1.34 |
| Exit | 3/16/2018 | 1.47 |
Please help me understand this news http://tim.ly/2DwXUj1 for CLRB. Why is this a good catalyst for a buy? It says that the Orphan Designation Status is Designated but it also says that it's not Not FDA Approved for Orphan Indication. What does that mean?
@ursula100 get in my http://tim.ly/sykesmc chat for Q&A
My challenge package arrives on Monday. Just waiting get to get my study on.
Good job! I saw that action. I got in at 1.16. Just a small amount. 200 shares. ER is Monday and Oppenheimer conference on Tuesday. If it holds its gains through premarket and ER, should ER come pre market, it could run. Such a low float of just 14.5 million with 11.29% off float shorted, with a short ratio of 10.12.
Ursula, basically an orphan drug is when that drug is the only drug that treats a certain issue. The company submits the application for orphan status. The fda then reviews it and decided if it is indeed an orphan drug. If it is, then they give it orphan status and with it comes faster approval times and other perks. The drug doesn’t need to be approved to have orphan designation.
@AHaedt thanks for your answer.
